0001477932-23-006099.txt : 20230814 0001477932-23-006099.hdr.sgml : 20230814 20230814161850 ACCESSION NUMBER: 0001477932-23-006099 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230814 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230814 DATE AS OF CHANGE: 20230814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VOLITIONRX LTD CENTRAL INDEX KEY: 0000093314 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 911949078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36833 FILM NUMBER: 231170542 BUSINESS ADDRESS: STREET 1: 1489 WEST WARM SPRINGS ROAD STREET 2: SUITE 110 CITY: HENDERSON STATE: NV ZIP: 89014 BUSINESS PHONE: 1 (646) 650-1351 MAIL ADDRESS: STREET 1: 1489 WEST WARM SPRINGS ROAD STREET 2: SUITE 110 CITY: HENDERSON STATE: NV ZIP: 89014 FORMER COMPANY: FORMER CONFORMED NAME: STANDARD CAPITAL CORP DATE OF NAME CHANGE: 19990812 8-K 1 vnrx_8k.htm FORM 8-K vnrx_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):  August 14, 2023

 

VolitionRx Limited

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36833

 

91-1949078

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of Incorporation)

 

File Number)

 

Identification Number)

 

1489 West Warm Springs Road, Suite 110

Henderson, Nevada 89014

(Address of principal executive offices and Zip Code)

 

+1 (646) 650-1351

(Registrant’s telephone number, including area code )

 

Not applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Each Exchange on which Registered

Common Stock,

par value $0.001 per share

 

VNRX

 

NYSE American, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

VOLITIONRX LIMITED

Form 8-K

Current Report

 

Item 2.02. Results of Operations and Financial Condition.

 

The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

On August 14, 2023, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended June 30, 2023.  The Company also confirmed its conference call to be held on August 15, 2023 at 8:30 a.m. U.S. Eastern Time.  Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

Number

 

Description

99.1

 

Press Release of VolitionRx Limited, dated August 14, 2023.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)

 

 
2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

VOLITIONRX LIMITED

 

 

Date: August 14, 2023

By:  

/s/ Cameron Reynolds

 

 

Cameron Reynolds

 

 

 

Chief Executive Officer & President

 

 

 
3

 

 

EXHIBIT INDEX

 

Exhibit

Number

 

Description

99.1

 

Press Release of VolitionRx Limited, dated August 14, 2023.

 

 
4

 

 EX-99.1 2 vnrx_ex991.htm PRESS RELEASE vnrx_ex991.htm

EXHIBIT 99.1

 

 VolitionRx Limited Announces Second Quarter 2023 Financial

Results and Business Update

 

Conference call to discuss financial and operational results scheduled for

Tuesday, August 15, at 8:30 a.m. U.S. Eastern Time

 

Henderson, Nevada, August 14, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the second quarter ended June 30, 2023. Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.

 

"I am delighted to report that we submitted a Breakthrough Device Designation Request to the FDA in June for our Nu.Q® technology in relation to sepsis. This was a milestone moment in our company’s history and for the first time we are in active discussions with the U.S. Food and Drug Administration. We believe that our case is strong, and we look forward to reaching agreement on a clear regulatory pathway to approval, for what we believe would be a pioneering product.”

 

“We continued making considerable progress with our Centers of Excellence in Europe for Nu.Q® NETs, with the first clinical paper resulting from one Center already submitted for peer review and look forward to hosting a Key Opinion Leader Roundtable Event focused on sepsis in September,” commented Cameron Reynolds, President and Group Chief Executive Officer of Volition.

 

“We are also getting closer to our goal of making our canine cancer screening and monitoring test accessible worldwide, through our current relationships, and through expected additional launches in large markets later this year.

 

“I am pleased to report that in the first half of 2023 we have already exceeded the total full year revenue we recorded in 2022 with total revenue to June 30th of $366,000. Revenue for the Nu.Q® Vet Cancer Test grew five-fold over the prior year, reflecting sales of the reference kits through our global supply agreements.”

 

An interview with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, and Terig Hughes, Group Chief Financial Officer of Volition.

https://youtu.be/E1sWyf4pC4U

 

Financial Highlights

 

·

Cash and cash equivalents as of June 30, 2023, totaled approximately $19.7 million compared with $10.9 million at the end of 2022.

·

Received approximately $17.6 million net of underwriter’s fees and commissions in cash through an underwritten public offering of its common stock in June.

·

Expect to receive a further $13 million in milestone payments from Heska Corporation and additional significant non-dilutive funding from several Belgian agencies.

 

 
1

 

 

Event:    VolitionRx Limited Second Quarter 2023 Earnings and Business Update Conference Call

 

Date:      Tuesday, August 15, 2023

Time:     8:30 a.m. U.S. Eastern Time

 

U.S. & Canada Dial-in: 1-877-407-9716 (toll free)

U.K. Dial-in: 0 800 756 3429 (toll free)

Toll/International: 1-201-493-6779

Conference ID: 13740530

 

Cameron Reynolds, President and Group Chief Executive Officer of Volition, will host the call along with Terig Hughes, Group Chief Financial Officer, Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, and Scott Powell, Executive Vice President, Investor Relations. The call will provide an update on important events which have taken place in the second quarter of 2023 and upcoming milestones.

 

A live audio webcast of the conference call will also be available on the investor relations page of Volition’s corporate website at https://ir.volition.com. In addition, a telephone replay of the call will be available until August 29, 2023. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13740530.

 

About Volition

 

Volition is a multi-national epigenetics company powered by Nu.Q®, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

 

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.

 

The contents found at Volition's website address and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition's website and YouTube are included in this document as inactive textual references only.

 

Media Enquiries:

 

Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com  +44 (0)7557 774620

 

 
2

 

 

Safe Harbor Statement

 

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition’s expectations related to the revenue opportunities and launches of product sales with Heska and other counterparties to agreements, the timing, completion, success and delivery of data from clinical studies, the receipt of additional non-dilutive funding, the potential uses, benefits and effectiveness of its Nucleosomics™ technology platform, including the Nu.Q® NETs test and the Nu.Q® Vet Cancer Test, and the timing and execution of Volition's strategy with the FDA. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests; a failure by the marketplace to accept Volition's Nu.Q® NETs test, Nu.Q® Vet Cancer Test or other products based on its Nucleosomics™ platform; Volition's failure to secure adequate intellectual property protection; Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; Volition will face fierce competition and its intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Forward-looking statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

 

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.  Additionally, unless otherwise specified, all references to “$” refer to the legal currency of the United States of America.

 

 
3

 

 EX-101.SCH 3 vnrx-20230814.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 vnrx-20230814_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity Incorporation State Country Code Entity Tax Identification Number Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Entity File Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name EX-101.CAL 5 vnrx-20230814_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 vnrx-20230814_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 vnrx-20230814_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 14, 2023
Cover [Abstract]  
Entity Registrant Name VolitionRx Limited
Entity Central Index Key 0000093314
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Aug. 14, 2023
Entity Incorporation State Country Code DE
Entity Tax Identification Number 91-1949078
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity File Number 001-36833
Entity Address Address Line 1 1489 West Warm Springs Road
Entity Address Address Line 2 Suite 110
Entity Address City Or Town Henderson
Entity Address State Or Province NV
Entity Address Postal Zip Code 89014
City Area Code 646
Local Phone Number 650-1351
Security 12b Title Common Stock,
Trading Symbol VNRX
Security Exchange Name NYSEAMER
XML 9 vnrx_8k_htm.xml IDEA: XBRL DOCUMENT 0000093314 2023-08-14 2023-08-14 iso4217:USD shares iso4217:USD shares 0000093314 false 8-K 2023-08-14 VolitionRx Limited DE 001-36833 91-1949078 1489 West Warm Springs Road Suite 110 Henderson NV 89014 646 650-1351 false false false false Common Stock, VNRX NYSEAMER false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / M " 4L0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !8@@Y7 M)!Z;HJT #X 0 &@ @ &K$0 >&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"% ,4 " !8@@Y799!YDAD! #/ P $P M @ &0$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" ( #:$P ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://vnrx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports vnrx_8k.htm vnrx-20230814.xsd vnrx-20230814_cal.xml vnrx-20230814_def.xml vnrx-20230814_lab.xml vnrx-20230814_pre.xml vnrx_ex991.htm http://xbrl.sec.gov/dei/2023 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vnrx_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "calculationLink": { "local": [ "vnrx-20230814_cal.xml" ] }, "definitionLink": { "local": [ "vnrx-20230814_def.xml" ] }, "inline": { "local": [ "vnrx_8k.htm" ] }, "labelLink": { "local": [ "vnrx-20230814_lab.xml" ] }, "presentationLink": { "local": [ "vnrx-20230814_pre.xml" ] }, "schema": { "local": [ "vnrx-20230814.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vnrx", "nsuri": "http://vnrx.com/20230814", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "vnrx_8k.htm", "contextRef": "From2023-08-14to2023-08-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://vnrx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "vnrx_8k.htm", "contextRef": "From2023-08-14to2023-08-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vnrx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001477932-23-006099-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-23-006099-xbrl.zip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�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